Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07601295 · ClinicalTrials.gov registry record · Phase 2
Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07601295: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT07601295 is a Phase 2 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07601295, a Phase 2 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class II-IV pulmonary arterial hypertension (PAH).
Interventions
- DRUG Tiprelestat (5 mg)
- DRUG Placebo (1 mL 0.9% saline solution)
- DRUG Tiprelestat (10 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07601295
The ClinicalTrials.gov registry entry for NCT07601295 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tiprelestat (5 mg) is the first listed.
NCT07601295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07601295 about?
NCT07601295 is a clinical study titled "Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)". The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class II-IV pulmonary arterial hypertension (PAH).
What is the current status of trial NCT07601295?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-07. Estimated completion is 2030-03.
What interventions are being tested in trial NCT07601295?
The interventions under investigation include: Tiprelestat (5 mg) (DRUG), Placebo (1 mL 0.9% saline solution) (DRUG), Tiprelestat (10 mg) (DRUG).
Who is sponsoring clinical trial NCT07601295?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.